Compare Cytokinetics Inc (CYTK) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Tapestry, Inc. — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Tapestry, Inc. trades at $135.74 (market cap $27.35B). The key difference: Tapestry, Inc. is far larger — about 2.5× Cytokinetics Inc's market cap, and Tapestry, Inc. pays a 1.18% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | TPR | |
|---|---|---|
Market Cap | $11.12B | $27.35B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $160.49 |
52-Week Low | $33.23 | $95.69 |
Enterprise Value | $11.59B | $30.20B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TPR is trading at $136.13, down 3.27% today, with a bearish technical signal despite strong analyst support. The company shows impressive profitability with 76.18% gross margins and 55.74% ROE, though recent earnings declined significantly from $816M in 2024 to $183M in 2025. Recent quarters have consistently beaten EPS expectations, with Q1 2026 reporting $1.66 versus $1.30 expected.
The stock presents a compelling growth opportunity with 75.6% analyst buy ratings and a $184.14 consensus target, representing 35% upside. However, elevated P/E of 41.5 and recent net income contraction warrant caution. Key risks include high debt levels and competitive pressures in the luxury retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
